EVOK Evoke Pharma Inc.

-0.06  -5%
Previous Close 1.12
Open 1.06
Price To Book 8.15
Market Cap 24,657,349
Shares 23,261,650
Volume 791,023
Short Ratio
Av. Daily Volume 586,888

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued April 2, 2019. Meeting with FDA regarding NDA resubmission potentially to be held around July 26, 2019.
Gimoti - EVK-001
Female diabetic gastroparesis

Latest News

  1. Is Evoke Pharma, Inc. (NASDAQ:EVOK) A Volatile Stock?
  2. Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA
  3. Evoke Pharma Reports First Quarter 2019 Financial Results
  4. Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
  5. Investors Who Bought Evoke Pharma (NASDAQ:EVOK) Shares Five Years Ago Are Now Down 92%
  6. Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
  7. The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
  8. Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA
  9. Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
  10. Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA
  11. Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication
  12. Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA
  13. Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results
  14. Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners
  15. Loss-Making Evoke Pharma, Inc. (NASDAQ:EVOK) Expected To Breakeven
  16. Evoke Pharma Reports Third Quarter 2018 Results
  17. Shareholders Should Check The Ownership Structure Of Evoke Pharma Inc (NASDAQ:EVOK)
  18. Generic-Drugs Stock Outlook: No Respite from Pricing Issues
  19. Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead
  20. Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA